Jul 5, 2017

Nima Farzan Discusses Vaccine Development for Overlooked Infectious Diseases at BIO 2017

Former CNBC correspondent Mike Huckman interviews PaxVax President and CEO, Nima Farzan, at this year’s BIO 2017 conference. Nima discusses vaccine development for underserved diseases, as well as differentiating PaxVax’s role as a leading independent vaccine company devoted to developing...


May 31, 2017

DoD Vaccine Research Saves Military, Civilian Lives

The Department of Defense (DoD) published an article discussing the military pursuit into disease prevention and vaccines, as U.S. service members deploy to areas rife with infectious diseases, such as malaria, Zika and other pathogens. Infections among troops is common...


May 16, 2017

Lyon Leads Trial to Test Vaccine Aimed to Protect Military Troops

Acute respiratory disease (ARD) due to infection with adenovirus is a major cause of morbidity at military training centers. In addition to ARD, adenovirus infection can cause sore throat, pneumonia, conjunctivitis, and urinary infections. Military recruits are particularly susceptible to...


Oct 31, 2016

We need a dose of global collaboration to fight Zika

Two years ago, Americans and Europeans watched in collective horror as a faceless, indiscriminate killer landed in their midst without warning. Fear and widespread anxiety were joined by deep frustration at the apparent unpreparedness to handle a threat of such...


Jun 10, 2016

FDA Approves Cholera Vaccine for US Travelers

WASHINGTON — Federal health officials have approved the first cholera vaccine intended to protect U.S. travelers from the potentially life-threatening disease. The Food and Drug Administration approved the liquid vaccine, called Vaxchora, for adults ages 18 to 64 who are...


May 17, 2016

Tackling Zika: Q&A With PaxVax CEO Nima Farzan

As mosquito season kicks into high gear and the threat of Zika transmission in the United States grows, the global health community is grappling with how to address not only the potential for large-scale outbreaks in the near-term but the...


Mar 4, 2016

Vaccines 2016: Big Bets for Global Threats

Another biotech firm with a California startup address that thinks it can leverage its expertise is Redwood City-headquartered PaxVax. “Along with many others, PaxVax is now in the early stages for developing a Zika vaccine,” according to CEO Nima Farzan....


Feb 10, 2016

Zika Update: Vaccine Race Swells, PaxVax CEO on How to Stop ‘Chasing Epidemics’

PaxVax plans to bring its candidate to animal trials during the first half of this year, CEO Nima Farzan told FierceVaccines. Farzan said, governments and nongovernmental organizations like the WHO should create economic incentives for companies to make vaccines for...


Feb 9, 2016

San Diego Company Testing Zika Vaccine

Scientist Jonathan Smith says PaxVax already has developed a vaccine for typhoid and is in the final stages of bringing a cholera vaccine to market. He said little is known about Zika, but a lot of what scientists think they...


Feb 7, 2016

Zika’s Threat Spurs Vaccine Research

PaxVax develops vaccines for infectious diseases in what the privately held company calls a "socially responsible' manner. It reports having raised more than $200 million from investors. This includes $105 million in December from Cerberus Capital Management, which is the...


Dec 16, 2015

FDA accepts PaxVax’s BLA for cholera vaccine, grants it priority review

Just a week after announcing a $105 million investment by Cerberus Capital, PaxVax is inching closer to getting its second vaccine--and potentially the first FDA-approved cholera vaccine--to market. The Redwood City, CA-based company announced Wednesday that the FDA accepted for...


Dec 9, 2015

Cerberus Capital management invests $105M in PaxVax

Redwood City, CA-based PaxVax currently markets one vaccine, Vivotif, the typhoid vaccine it acquired from Johnson & Johnson's ($JNJ) Crucell in July 2014. But PaxVax could be on the way to adding its cholera candidate, Vaxchora, to the list thanks...


1 of 3123